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ABSTRACT 
Various pathological conditions, such as cancer, osteoporosis, AIDS, 
tuberculosis, and other pathologies, require the concurrent use of multiple drugs, 
known as combination therapy or polytherapy, for effective treatment. The concurrent 
delivery of multiple drugs in a single dosage form, such as a tablet, capsule or 
parenteral, has been demonstrated in a number of products, but current technologies 
for multiple drug delivery remain limited for broad application. Physicochemical 
incompatibility, limited aqueous and lipid solubility, and chemical instability of the 
individual drugs, as well as detrimental drug-drug and drug-excipient interactions 
within the multiple-component dosage form, may all compromise the development of 
stable, multiple drug delivery systems.   
Liposomes have been employed for the delivery of pharmaceuticals, 
nutraceuticals, and cosmetics for a number of years.  Liposomes are now emerging as 
potential tools for the delivery of multiple therapeutic and diagnostic agents in a single 
dosage form. While useful for some pharmaceutical applications, liposomes may have 
certain limitations, such as low drug encapsulation efficiency, poor mechanical and 
physical stability, and fragile structures that can lead to premature release of 
encapsulated drug before reaching the target site. Empirical attempts have been made 
to assemble liposomal structures and divide the space controllably and spontaneously 
at a nanometer scale into hydrophobic and hydrophilic regions. By understanding the 
nature of the different microenvironments located within liposomes, multiple drugs 
with a wide range of physiochemical properties may be incorporated into 
appropriately designed liposomal structures. Various modifications can be made to the 
  
composition and surface modification of liposomes in order to control their size, 
enhance their stability, and incorporate a combination of multiple therapeutic and 
diagnostic agents, thereby producing a polyfunctional „theranostic‟ liposome for 
improved therapeutic compliance and clinical effectiveness.   
We hypothesize that in order make these liposomes and optimize the drug 
delivery it is necessary to understand the liposome formation procedure with emphasis 
on the nature of both aqueous and lipid microenvironments so that suitable 
combinations of therapeutics and diagnostics can be identified and incorporated into 
the liposome system. Optimization of these nanostructures is necessary in order to 
enhance their stability while emphasizing the use of GRAS (generally regarded as 
safe) materials and conforming to compendial standards for injectables. This is 
followed by characterization of these delivery devices in terms of their structure, drug 
loading, size, morphology, thermal characteristics, reproducibility of formulation, and 
stability using microscopic, light, electric, magnetic, chromatographic, and thermal 
analysis, as well as an appreciation of the interaction of encapsulated small molecules 
with lipid components. Finally, an evaluation of the performance of these vesicles as 
controlled delivery devices using an externally applied magnetic field in order to 
trigger bolus or pulsatile drug release is summarized.    
This study has provided important predictive information regarding the 
formation, formulation, stability, and performance characteristics of theranostic 
liposomal delivery systems in the context of the specific physicochemical properties of 
selected combinations of chemically diverse drugs and other small molecules that are 
nevertheless clinically relevant. It is hypothesized that these data will be useful in the 
  
design and optimization of analogous systems containing drugs with similar 
properties.  The use of a magnetic field-induced release mechanism will afford data 
regarding the utility of this controlled release mechanism in multiple drug-containing 
systems.  The successful design and characterization of these systems may lead to 
improved therapeutic efficacy of combination drug therapy, increased patient 
compliance, ease of use, and targeted drug delivery for reducing both dosing 
frequency and toxicity. 
The work has been prepared for publication and included in the thesis as follows: 
1) Manuscript 1: Design and development of liposomes for concurrent, controlled 
delivery of therapeutic agents for bone osteoporosis (in preparation Pharmaceutical 
Research).   
2) Manuscript 2: The interactions and effects of di- and polyphenolic compounds 
on lipid vesicles (in preparation Lipid Research). 
3) Manuscript 3: The design and development of liposomes for the concurrent, 
controlled delivery of multiple therapeutic agents for improving the efficacy of 
pancreatic cancer treatment (in preparation Journal of Controlled Release). 
 
Manuscript 1: Radiofrequency-activated nano liposomes for controlled multi-
drug delivery. 
This manuscript focuses on the use of a hydrophilic tetracycline antibiotic, 
doxycycline HCl, and a hydrophobic, estrogenic anti-osteoporosis drug, raloxifene 
HCl, and their incorporation into liposomes. These drugs are incorporated into the 
different aqueous and lipid microenvironments of the liposome. The delivery of these 
  
drugs is controlled by using hydrophobic iron oxide nanoparticles that are coated with 
oleic acid. Given the disparate physicochemical characteristics of the two drugs, there 
were some untoward compatibility and stability issues that arose.  These instabilities 
were addressed by optimizing the drug concentrations and integrating block 
copolymers in order to sterically stabilize the liposomes.  
In-depth analyses and characterization of these delivery devices, including 
size, morphology, reproducible formulation, drug loading and release, and stability, 
followed by their optimization for drug delivery in compliance with the compendial 
standards and in vitro release patterns, were also performed.  
Since the drugs have different physiochemical properties, their interactions 
with the liposomal bilayers were different. These interactions were carefully analyzed 
using various light, magnetic, electric and thermal techniques and, where appropriate, 
NMR spectrometry. The rate and extent of drug release from these liposome 
constructs, with and without magnetic nanoparticle-induced drug release, was studied 
in a physiologically relevant media (137 mM phosphate buffered saline, pH 7.4). 
During this study, we observed that raloxifene HCl (a di- phenolic, hydrophobic drug) 
had a pronounced effect on the transition temperature of liposomes that led to the 
investigation of the effect of various other lipophilic, di- and polyphenolic compounds, 
on liposomes. This work is shown in the following manuscript. 
  
 
 
  
Manuscript 2: The interactions and effects of di- and polyphenolic compounds on 
lipid vesicles. 
This study focuses on the interactions of various hydrophobic, di- and 
polyphenolic drugs and nutraceuticals, including raloxifene, garcinol, resveratrol, 
quercetin and bisphenol A, with DPPC liposomes. These drugs and nutritional 
compounds belong to BCS classes II and IV. As such, they all have very low aqueous 
solubility, which would suggest a tendency to be incorporated into the hydrophobic 
bilayers.  In addition, the BCS Class IV compounds also have very low tissue 
permeability. Due to the likely interaction of these agents with the vesicular lipid 
bilayers, they were capable of changing the thermodynamic properties, packing 
parameter, and stability of these bilayers. These changes in the liposomal properties 
was characterized by studying their zeta potential, particle size as a function of time, 
nano Differential Scanning Calorimetry (nano-DSC), 
1
H-NMR (proton nuclear 
magnetic resonance) and 
31
P-NMR (phosphorus nuclear magnetic resonance) 
spectrometry. It was hypothesized that these phenolic compounds may interact with 
the phosphate head groups and/or the acyl chains of the DPPC and thereby increase 
the transition temperature of DPPC bilayers. With an increase in the transition 
temperature, the liposomes were expected to become more thermodynamically stable, 
as a greater amount of energy would be required to convert them from the rippled gel 
to the liquid crystalline phase. Any increased exposure of the phosphate groups to the 
external suspension media induced by polyphenolic interactions might lead to an 
increase in the negative surface charge, as determined by zeta potential measurements. 
This increased surface charge can lead to repulsive forces between the liposomes and 
  
might further enhance liposome stability. The overall effect of polyphenolics on DPPC 
liposomes, if favorable, might be utilized to form stable liposomes characterized by 
minimal drug leakage, which is a common disadvantage of liposomal drug delivery 
systems, as well as lead to extended shelf life and improved handling on shipping and 
storage.  
   
Manuscript 3: The design and development of liposomes for the controlled 
delivery of multiple therapeutic drugs for pancreatic cancer. 
In this study, liposomes comprising 1, 2-Dipalmitoyl-sn-glycero-3-
phospocholine monohydrate (DPPC) were used to encapsulate a combination of 
chemosensitizing, chemotherapeutic, and tumor resistance modulating agents, namely 
gemcitabine and the COX-2 (cyclooxygenase 2) inhibitor celecoxib. The liposomes 
were first loaded with each individual drug and then characterized with various light, 
magnetic, electrical, and thermal techniques. There was a difference in the release 
pattern of the drugs, perhaps due to differences in their physiochemical properties and 
likely disparate interactions with the bilayers and solubility in the aqueous core. After 
evaluating the single-drug containing liposomes, analogous characterization and 
evaluation of the performance of the liposomes containing combinations of the active 
agents were conducted. The stabilized liposomes that had uniform particle sizes 
loaded with both the drugs and magnetic nano particles were incubated for 48 hours 
with BxPc-3 human pancreatic cancer cells. Cell viability was then determined by 
performing an MTT assay. In order to assess the utility of magnetic nanoparticle-
induced drug release in this in vitro system, analogous experiments were carried out 
  
using one or more representative liposome system with and without magnetic 
nanoparticles.  The results were compared to those obtained from analogous 
experiments assessing the cytotoxicity of combinations of free drug.  It was found that 
the liposomal formulations containing drug combinations induced maximum cell 
death, as the chemosensitizers likely increased the sensitivity of the BxPc-3 cell lines 
towards gemcitabine.  
 ix 
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Manuscript 1: Radiofrequency-activated nano liposomes for controlled multi-
drug delivery. 
This manuscript is being prepared for submission to Pharmaceutical Research. 
 
Manuscript 2: The interactions and effects of di- and polyphenolic compounds on 
lipid vesicles. 
This manuscript is being prepared for submission to Lipid Research. 
 
Manuscript 3: Design and development of liposomes for the controlled delivery of 
multiple therapeutic drugs for pancreatic cancer. 
This manuscript is being prepared for submission in Journal of Controlled Release. 
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ABSTRACT 
An important goal in therapeutics is the delivery of multiple drugs via delivery 
vehicles that are stable, but release their payload through a triggering mechanism.  As 
an example of such a multifunctional vehicle, we have produced poloxamer stabilized 
DPPC-based nano liposomes containing doxycycline HCl (DOX), raloxifene HCl 
(RAL) and magnetic nano particles (MNP‟s) in the membrane wall. We observed 
minimal release of the encapsulated drugs until electromagnetic radiation at RF 
frequencies was applied. RAL had a pronounced stabilizing effect on the liposomes 
and the release of DOX from the MNP containing liposomes was evident after 
radiation. Using a range of analytical tools, we show how intermolecular interactions 
are key to the stability and release of encapsulants from these vehicles.  These studies 
give important insight into the design and optimization of multi-drug containing 
delivery vehicles for advanced therapeutic applications. 
 
 3 
 
1. INTRODUCTION 
Liposomes and other lipid-based vesicular systems have been investigated for over 40 
years as drug delivery systems for various therapeutic agents, such as anticancer, 
antifungal, analgesic, gene therapy, and other active pharmaceutical ingredients.
1
 
Liposomes are versatile candidates for the delivery of multiple cargos, as their 
interfacial and surface properties can be easily modified.
2
 The hydrophilic components 
can be dissolved in the aqueous cores of the liposomes while the hydrophobic 
compounds can be incorporated into the bilayers.
3
 However, the stability of liposomes 
is always a major concern,
4
 leading to liposomal cargo leakage, and thus a decline in 
the availability of the drugs at specific sites.   
Various attempts have been made in the past to stabilize liposomes, such as the 
inclusion of cholesterol in order to increase the bilayer rigidity, using phospholipids of 
high transition temperatures, polymerization of modified lipids, freeze-thawing and 
the insertion of block copolymers.
5-7
 Furthermore, the stability of liposomes can also 
be achieved by steric hindrance with the aid of poloxamer block co-polymers known 
as Pluronics® (PL).
8
 By using various grades of PL‟s that differ in their respective 
hydrophilic (PEO) and hydrophobic (PPO) blocks, liposomes can be stabilized.
9
 With 
the inclusion of PL‟s during thin film formation procedure, i.e., dissolving it in the 
organic solvent along with the lipid, the mechanism of desorption or “squeezing out” 
can be prevented which might be the case if they were added after liposomes were 
formed. Thus, PL‟s can become an integral part of the vesicles and aid in their stability 
for an enhanced period of time.
10,
 
11
 
 4 
 
Since the release of hydrophilic drugs encapsulated in the liposomal core is driven by 
passive diffusion, the insertion of PPO chains into the bilayers hinders this transport.
12
 
An enhanced rigidity of the bilayer imparted by the inclusion of hydrophobic drugs 
may further reduce this release rate. Moreover, release of hydrophobic compounds 
embedded within the bilayer can be challenging due to the strong hydrophobic 
interactions between the drugs and the lipid chains. A high frequency AC magnetic 
field has been reported to trigger the drug release from liposomes and polymersomes 
with the use of super paramagnetic iron oxide nano particles (SPIO).
13,14
 These SPIO‟s 
are biocompatible with minimal in vivo toxicity and have also been used as diagnostic 
agents.
15
 
In this investigation we report the formulation of multiple drugs using sterically 
stabilized liposomes with the aid of a triblock copolymer and the concurrent use of 
radio frequency magnetic fields with an aim to trigger the release of encapsulated 
hydrophilic drug. A highly water soluble BCS Class I drug, doxycycline 
hydrochloride (DOX) was used as a model drug and encapsulated into the hydrophilic 
cores of the liposomes, whereas a poorly water soluble model drug raloxifene 
hydrochloride (RAL) was incorporated into the liposome bilayer. The liposomes were 
stabilized using triblock copolymers pluronics and a triggered release was obtained by 
incorporating SPIO into the liposome bilayer using a high frequency AC magnetic 
field. 
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2. MATERIALS AND METHODS 
2.1. Materials. 1, 2-Dipalmitoyl-sn-glycero-3-phospocholine monohydrate (DPPC) 
was purchased from Corden Pharma (Colorado, USA). Doxycycline hydrochloride 
(DOX) and raloxifene hydrochloride (RAL) were purchased from Fisher Scientific 
(Pittsburgh, PA). All Pluronic polymers were purchased from BASF (Parsippany, NJ). 
Cellulose membranes (Spectra/Por MW cutoff 3500 Da), used for dialysis and drug 
release tests, were obtained from Spectrum Laboratories, Inc. (Houston, TX). 
Phosphate buffered saline (PBS) tablets were purchased from MP Biomedicals (Solon, 
OH). SPIO maghemite nanoparticles (5 nm, 24 mg ml
-1
 or 187.9 mM Fe2O3) dispersed 
in chloroform were purchased from Ocean Nanotech (Springdale, AR). On the basis of 
the density of maghemite (4.9 g cm
-3
), 24 mg ml
-1 
is equivalent to 1.43×10
17 
particles 
ml
-1
. All other reagents were purchased from Fisher Scientific and were of analytical 
grade. 
 
2.2. Liposome preparation. Vesicles were prepared at a 17 mM lipid concentration 
for all formulations. For the 
31
P-NMR, the vesicles were made in 90:10 (water: D2O). 
The vesicles were prepared in 4 ml batches by film rehydration (3 ml for dialysis and 
drug release studies and 1 ml for characterization) as described by Chen et al.
16
 The 
samples were further diluted to a lipid concentration of 5.6 mM for TEM, 1 mM for 
DLS and zeta potential, and 0.1 mM for nano-DSC. When individual drugs were 
loaded in liposomes, their final concentration was maintained at 2 mM. When the two-
drug combination was encapsulated, their concentrations were reduced to 0.5 mM, as 
higher two-drug concentrations resulted in vesicular aggregation and instability. The 
 6 
 
procedure was same for all the formulations except for the step in which various 
components were added differed for different formulations. DOX- containing 
liposomes were prepared by dissolving 50 mg of DPPC in 4 ml of chloroform. 
Chloroform was removed by rotary evaporation at 50 °C (above the DPPC melting 
temperature) starting at 450 mbar for 30 min, then decreased to 300 mbar for 30 min, 
and finally 200 mbar for 30 min. This lipid film was kept under vacuum for 2 hours at 
room temperature to remove traces of chloroform. It was then rehydrated with a 2 mM 
DOX in 137 mM PBS for 2 hours at 50 °C. RAL liposomes were analogously 
prepared. RAL and DPPC were dissolved in a 3:1 ratio of chloroform: methanol due to 
the insolubility of RAL in pure chloroform. The organic solvents were removed by 
rotary evaporation at 50 °C (above the DPPC melting temperature) starting at 450 
mbar for 30 min, then decreased to 300 mbar for 30 min, and finally 200 mbar for 30 
min. This lipid film was kept under vacuum for 2 hours at room temperature to 
remove traces of organic solvents. The film was rehydrated with 137 mM PBS and the 
final RAL concentration in the formulation was 2 mM. The magnetic nano-particles 
(MNP‟s), RAL, DOX and Pluronic® P84 (P84) containing liposomes were prepared 
in a similar way by adding the MNP‟s [lipid/MNP (L/N) ratios of 5000:1, 10000:1 and 
20000:1] and P84 to the organic solvent mixture containing lipid and RAL and 
following the film formation as described above using rotary evaporator and 
rehydrating the film with 0.5 mM DOX in 137 mM PBS. The resulting aqueous 
dispersions were then sonicated for 1 hr using a bath sonicator.  
 
 7 
 
2.3. Cryogenic Transmission Electron Microscopy (Cryo-TEM). Cryo-TEM 
samples were prepared at 25 °C using a Vitrobot (FEI Company), which is a PC-
controlled robot for sample vitrification. Quantifoil grids were used with 2 μm carbon 
holes on 200 square mesh copper grids (Electron Microscopy Sciences, Hatfield, PA). 
Samples were first equilibrated within the Vitrobot at 25 °C and 100% humidity for 30 
min. After immersing the grid into the sample, it was then removed, blotted to reduce 
film thickness, and vitrified in liquid ethane. The sample was then transferred to liquid 
nitrogen for storage. Imaging was performed in a cooled microscopy stage (Model 
915, Gatan Inc., Pleasanton, CA) at 200 kV using a JEOL JEM-2100F TEM (Peabody, 
MA). 
 
2.4. Energy dispersive X-ray scattering (EDS). EDS (Model INCAx-act, Oxford 
Instrument, K) was used to detect elemental iron from the magnetic nanoparticles 
within the iron oxide nanoparticle-loaded liposomes. EDS was conducted during 
cryogenic imaging with 158 s of live time and 92 s of dead time. 
 
2.5. 
31
Phosphorus- Nuclear Magnetic Resonance (
31
P-NMR). The 
31
P-NMR spectra 
were acquired on an Agilent NMRS 500 NMR spectrometer operating at 202.3 MHz 
using a 5mm NMRone probe. The probe temperature was thermostated at 37 °C for all 
experiments. Liposome formulations analyzed by NMR were prepared as previously 
described with the exception that 10% D2O in water was used as a solvent in order to 
provide a deuterium lock signal. NMR data were collected for 60 K scans with a 35.7 
kHz sweep width using 131 K data points. Acquisition time was 1.3 sec with a 
 8 
 
relaxation delay of 0.5 sec. The data were processed with mnova program V8.1 
Mesterlab research SL. A line broadening of 50 Hz was applied to all spectra. All 
spectra were indirectly referenced to H3PO4 set to 0 ppm. Data were acquired without 
spinning. 
 
2.6. Nano Differential Scanning Calorimetry (nano-DSC). Nano-DSC was 
performed using a TA Instruments Nano DSC (New Castle, DE, USA). Samples at a 
concentration of 0.1 mM lipid were degassed under vacuum for 30 min before loading 
into a 0.6 mL capillary cell. The cell was then pressurized with nitrogen to 1 atm and 
equilibrated at 25 °C. The sample was scanned at 1 °C min
-1
 over a range of 25 °C to 
60 °C.  
 
2.7. High Performance Liquid Chromatography (For quantification of 
dissolution). The HPLC system comprised a Hitachi La Chrome Elite equipped with a 
PDA detector and an automatic injector with a loop volume of 0.1 ml. For DOX 
quantification, an Agilent Zorbax SB C8 (5 micron, 4.6 x 250 mm) column was used. 
The mobile phase consisted of 0.02 M oxalic acid/ methanol/ acetonitrile (65/25/10) 
with a final pH of 2.5. The flow rate was 1 ml min
-1
 with an injection volume of 90 µl 
and a detection wavelength of 350 nm. The limit of detection of DOX using this 
method was 20 nM. The calibration curve in PBS was R
2 
= 0.999. The column used 
for RAL quantification was a Luna 3 micron C18 (2) 150 x 4.6 mm with a mobile 
phase comprising 0.05 M ammonium acetate/ acetonitrile (67/33) with a final pH of 
4.0. The flow rate was 1 ml min
-1
 with an injection volume of 90 µl and a detection 
 9 
 
wavelength of 287 nm. The limit of detection was 20 nM and the calibration curve in 
PBS was R
2
 = 0.9997. The R
 2 
linearity gives a correlation between the concentration 
of drug and the area under the curve of the HPLC chromatogram. R
2 
value of 0.999 
over a range of 20 nM to 200,000 nM suggests accurate quantification of drug derived 
from corresponding HPLC chromatograms.  
 
2.8. Dynamic Light Scattering. DLS measurements were performed using a Malvern 
Instruments Zetasizer Nano ZS with a backscattering detector angle of 173° and a 4 
mW, 633 nm He-Ne laser (Worcestershire, UK). For size distribution studies, 1 ml of 
the liposome formulations was analyzed in an optical grade polystyrene cuvette at 37 
°C. Before analysis, the samples were stored at 37 °C and then analyzed after 24 
hours. 
 
2.9. Radio frequency (RF)-induced drug release. Drug-loaded liposomes containing 
magnetic nanoparticles were placed in a copper heating coil (3 turns at 4.5 cm mean 
diameter) around a custom-designed polycarbonate container with a holder for 
SpectraPor dialysis tubing. Heating was conducted as a function of time and 
electromagnetic field strength using a 1 kW Hotshot (Ameritherm Inc., Scottsville, 
NY) operating up to 250 A and 281 kHz. Samples were collected from the drug 
dissolution media at serial time points during the drug release experiments, and drug 
concentrations as a function of time were then determined using HPLC. 
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2.10. Dialysis and Release studies. The dialysis experiment were conducted at room 
temperature (25 ± 0.5 °C) using 3.5 kDa tubular cellulose acetate membranes for 24 
hours in 137 mM PBS with constant stirring and replacement of the dissolution media. 
The dissolution media was collected and analyzed by HPLC for unencapsulated drug 
in order to calculate the drug loading capacity of the liposomes.  Drug release studies 
were performed using the same dialysis tubing. The experiments were carried out in 
137 mM PBS at 37 ± 0.5 °C and a pH of 7.4 with a stirring speed of 75 rpm using a 
0.5 inch magnetic stirrer. Fresh media was replaced after the sampling was done at 
regular time intervals. 
 
3. RESULTS AND DISCUSSION 
3.1 Morphological characterization of the vesicles. It is essential to interpret the 
structural characteristics of the liposomes such as their size and shape with the 
incorporation of P84, MNPs, DOX and RAL. Hence, in order to study the 
morphological characteristics and incorporation of MNPs into the bilayer, Cryo-TEM 
and EDS analysis of the liposomes was performed.  The morphological characteristics 
of liposomal formulations at 2 mM individual drug concentrations are shown in Figure 
1 (a, b). 
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Figure 1. DOX and RAL release from DPPC liposomes carried out at 37 °C and pH 
7.4 in 137 mM PBS. 1.88 mM of DOX and 1.98 mM RAL was encapsulated after 20 
hours of dialysis which corresponds to encapsulation efficiency of 94.5% and 99.3% 
respectively. Cryo-TEM images of corresponding (a) DOX and (b) RAL containing 
liposomes indicating no difference in the morphology. Scale bar is 200nm for the 
TEM images. 
 
Both DOX- and RAL-containing liposomes were similar in shape with a bilayer 
thickness of 5 nm, suggesting that the drugs alone did not influence liposomal 
morphology. The formulations containing both P84 and MNP‟s were also analyzed for 
their morphology and elemental composition (Figure 2).  
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Figure 2. Cryo- TEM images (a) and EDS scans (b) of liposomes containing DOX, 
RAL and P84 which shows absence of iron peak at 6.4 keV. Cryo-TEM images and 
EDS scans of liposomes containing DOX, RAL, P84 and MNP‟s before (c, d) and 
after (e, f) RF exposure. The L/N ratio was 10000:1 for these formulations. Yellow 
arrows indicate the presence of MNP‟s in the bilayers. The round shape of liposomes 
was converted to angular showing the influence of RF heating on the bilayers. Scale 
bar is 200nm. 
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Formulations that did not contain MNP‟s did not show any iron peak. Formulations 
containing MNP‟s depicted distinct iron peaks at 6.4 KeV (indicated with yellow 
arrows). There was no evidence of the presence of MNP‟s or aggregates of MNP‟s 
outside of the liposomes, suggesting that the MNP‟s were successfully incorporated 
into the lipid bilayers as previously reported.
16
 The EDS scans were taken in the 
specific areas of the grid that had liposomes and no prevalent iron oxide nano 
particles. Thus, it is proved that iron oxide nano-particles were successfully 
incorporated into the bilayers that triggered the cargo release by using external 
magnetic field.  
 
3.2. Stability of liposomes. Polydispersity index (PDI) was obtained from photon 
correlation spectroscopic analysis, giving a dimensionless number extrapolated from 
the autocorrelation function. Samples with very broad size distribution have 
polydispersity index values > 0.7. The PDI of all liposome formulations assessed in 
the present study was detected below 0.3 suggesting a small particle size distribution 
and homogenous liposomal formulations. The liposomal formulations were further 
characterized by DLS at various time points to estimate the stability at physiological 
temperature (Figure 3).  
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Figure 3. Hydrodynamic diameter of liposomal formulations indicating stability 
attained by P84.  
 
By taking into consideration the goal of multiple drug loading, when 2 mM of both 
DOX and RAL were loaded into analogous liposomal systems, large aggregates 
formed within a couple of hours, perhaps because of the adsorbed DOX. In order to 
prepare stable liposomes containing both drugs, their concentration was reduced from 
2 mM to 0.5 mM each considering this limitation of colloidal stability maybe due to 
DOX adsorption. The reduction in drug concentration did not improve the stability and 
since we aimed to make stabilized nano liposomes, poly (ethylene oxide)-poly 
(propylene oxide)-poly (ethylene oxide) triblock copolymers, or generally known as 
poloxamers such as Pluronics® (PL) were added to the bilayers to enhance vesicular 
stability.
8
 Pluronics® F-127 and F-108 are proven to increase the mechanical stability 
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of lipid based vesicular systems, such as dioleoylphosphatidylethanolamine 
liposomes.
17
 Therefore, various grades of PL‟s were incorporated at different weight 
percent into the liposomal bilayers in order to stabilize the liposomes containing 0.5 
mM of both DOX and RAL respectively (Table 1).  
 
Pluronic grade  Monomer ratio  
F108  PEO132-PPO50-PEO132  
F68  PEO76-PPO30-PEO76  
F127  PEO100-PPO65-PEO100  
P84  PEO19-PPO39-PEO19  
 
Table 1. Various grades of Pluronics used to stabilize the liposomes along with the 
individual monomer ratios of PEO: PPO. 
 
Among the four grades of PL that were assessed as liposome stabilizers, only P84 
enhanced vesicular stability. Since P84 has the lowest hydrophilic / hydrophobic 
(PEO/ PPO) ratio, the hydrophobic PPO chains of this particular polymer grade might 
undergo the most pronounced insertion into the hydrophobic bilayers of the liposomes, 
resulting in mechanical stabilization. With the increase in the hydrophilic moiety of 
the copolymer PEO, there is a possibility of “squeezing out” of the copolymer from 
the lipid bilayers. With P84 at 1:10 (PL:DPPC) w/w ratio, the optimum amount of 
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hydrophilic PEO chains on the surface and PPO chains inserted into the bilayers of 
each liposome likely improved vesicular stability due to steric hindrance.
18
 
 
3.3. Characterization of the bilayer. The change in the transition temperature of a 
vesicular lipid bilayer depends on the presence of other chemical species and their 
subsequent interaction within the different domains of the vesicles. The interactions of 
DOX, RAL and combinations thereof were thermally analyzed with nano DSC (Figure 
4). 
28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62
K
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m
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Temperature (°C)
 DPPC
 DPPC+2mM Dox
 DPPC +2mM Ral
 DPPC+P84
 DPPC+2mMRal+P84
 DPPC+Dox+Ral+P84
 DPPC+0.5 mM Ral
 DPPC+0.5mMRal+aP84
 10000:1
 20000:1
 
Figure 4. Nano DSC thermographs of the liposomal formulations. RAL increased the 
Tm of the liposomal bilayer, whereas the Tm was reduced using MNPs and peak 
broadening was observed with P84. DOX and P84 did not have any effect on the Tm. 
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Formulations ΔH 
(Kcal/mol) 
ΔS 
[Kcal/(mol.K)] 
Tm 
(°C) 
Blank DPPC 8.43 0.1963 42.96 
DPPC + 2mM Dox  11.95 0.2856 41.86 
DPPC + 2mM Ral  12.12 0.2463 49.24 
DPPC + P84 8.050 0.1928 41.78 
DPPC + 2mM Ral + P84 11.03 0.2248 49.08 
DPPC + 0.5mM Dox + 0.5mM Ral + 
P84 
12.62 0.2752 45.88 
DPPC + 0.5mM Ral + P84 11.51 0.2590 44.45 
DPPC + 0.5mM Ral 10.98 0.2312 47.50 
 
Table 2. Enthalpy, entropy and the transition temperatures of liposomal formulations 
measured by nano DSC indicating the drug lipid interaction.  
 
For drug-free DPPC control liposomes, a transition of 8.43 Kcal mol
-1 
occurred at 
42.96 °C (Table 2). This transition is consistent with the conversion of the rippled gel 
phase to the liquid crystalline phase.
19
 The inclusion of DOX into analogous DPPC 
vesicles did not significantly alter the Tm, suggesting that DOX was not associated 
with the bilayers and was instead incorporated in the aqueous core or partly adsorbed 
onto the surface. Although the PPO moieties of P84 were hypothesized to be present 
in the bilayers, the inclusion of P84 did not affect the Tm of DPPC vesicles. However, 
peak broadening was detected, suggesting a decrease in the cooperativity of the phase 
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transition as reported with the addition of cholesterol.
20
 This peak broadening effect 
was only demonstrated in presence of P84 and/or MNP‟s that are coated with 
hydrophobic oleic acid. This is attributed to interdigitation of the PPO or oleic acid 
chains in the bilayers with absence of any ring structure which is the case with RAL. 
Upon addition of 2 mM RAL to liposome formulations; a significant phase transition 
of 12.12 Kcal mol
-1 
at 49.24 °C was observed. The addition of 0.5 mM RAL showed a 
transition of 10.98 Kcal mol
-1
 at 47.5 °C. This RAL-induced shift in to a higher Tm 
was directly proportional to the concentration of RAL included in liposome 
formulations. The higher Tm suggests more thermodynamic and mechanical stability 
of the liposomes. Various studies have revealed that an increase in mechanical 
stability is associated with an increase in bilayer rigidity and, in turn, colloidal 
stability.
21
 Thus, RAL-containing liposomes were more stable than analogous, DOX-
containing liposomes. The inclusion of MNP‟s (L/N ratio of 10,000/1) decreased the 
Tm significantly to 39.02 °C.  This MNP-induced change in the Tm was inversely 
proportional to the concentration of MNP‟s incorporated into the vesicular systems 
(Tm = 41.21°C for L/N ratio of 20000/1). This is due to the hydrophobic interaction of 
the oleic acid coating on the MNP‟s with the lipid chains in the vesicle bilayer, 
thereby forming a less rigid lipid bilayer. Although the apparent reduction in bilayer 
rigidity might theoretically have led to leaky liposomes, drug release studies did not 
show any leakage from the MNP-containing liposomes in the absence of radio 
frequency (RF) heating.  
The effect of incorporating DOX, RAL and P84 in DPPC liposomes was also 
illustrated by 
31
P-NMR, as shown in Figure 5.  
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Figure 5. 
31
P-NMR spectra after 60 K scans for liposomes containing 1) Blank DPPC 
2) DPPC and 2 mM DOX and 3) DPPC and 300 µM P84 4) DPPC and 2mM RAL and 
5) DPPC with 0.5mM RAL and DOX and 300 µM P84 dispersed in a 1:9 (D2O:H2O) 
solvent equilibrated at 37 °C. No shielding effect was detected for DOX or P84 
containing liposomes. Black arrows indicate the shift in the upward field due to 
shielding effect of the aromatic rings present in RAL. 
 
With a blank DPPC liposome, one single sharp peak was obtained, a characteristic 
indicator of small, unilamellar vesicles.
22
 With the addition of either DOX or P84 to 
DPPC liposomes, neither a chemical shift nor a change in the shape of the NMR signal 
was detected. The presence of small, unilamellar vesicles was also confirmed with 
cryo-TEM imaging. Thus, it was concluded that, unlike RAL, neither DOX nor P84 
affect the orientation or the environment of the phosphate head groups in the 
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liposomal bilayers.  In contrast, with the incorporation of RAL, an additional 
resonance appears upfield of the DPPC resonance.  This upfield resonance (black 
arrows) is the result of additional shielding due to the rigid aromatic rings of RAL 
which oriented themselves in the lipid bilayers in the proximity of the phosphate head 
group, which is associated with increased exposure of the phosphate groups to the 
vesicle surface. The magnitude of this shielding effect was directly proportional to the 
concentration of RAL incorporated into DPPC liposomes.
23
 Thus, the orientation of 
different chemical species (such as drugs, polymer, and MNP‟s) in various regions of 
the liposomes was confirmed and in keeping with the desired optimized formulation 
design. 
 
3.4. Drug release. DOX being hydrophilic due to the high polar surface area and 
protonated, charged tertiary amine, and RAL being relatively hydrophobic due to the 
presence of large domains of hydrophobicity, including a phenyl moiety, a 
benzothiophene heterocycle, and an aliphatic chain (Figure 6) were incorporated into 
different regions of the liposomes.  
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Figure 6. Chemical structures of DOX (left) and RAL (right).  
 
DOX HCl has a high aqueous solubility and permeability and hence belongs to 
biopharmaceutical classification system (BCS) Class I, whereas RAL belongs to BCS 
Class II which comprises drugs of low solubility but high gastrointestinal 
permeability, and has a reported log P of 5.7.
24
 The release of these drugs having 
different physiochemical properties from different regions of the liposomes was 
performed under physiological conditions with and without the use of an external 
magnetic field. Liposomal formulations were subjected to dialysis studies prior to the 
drug release in order to remove unentrapped drugs from the hydration media. The 
dialysis experiment was carried out until a constant drug concentration was obtained 
from assayed dialysate samples, indicating that equilibrium had been achieved and no 
unentrapped material was present in the dissolution sample. At the end of the dialysis 
experiment, mass balance equations were used to calculate the encapsulation 
efficiency of the liposomal formulations. At a 17 mM DPPC concentration, 1.88 mM 
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(94.56% theoretical) of DOX and 1.98 mM (99.35% theoretical) of RAL were 
successfully encapsulated.  
While performing individual drug release studies, it was observed that DOX entrapped 
in the hydrophilic core was released from the liposomes, most likely due to passive 
diffusion driven by a concentration gradient across the vesicular lipid bilayer. About 
1200 nM of DOX was released after 24 hours of dissolution. RAL, which was present 
within the lipid bilayers, showed even a lesser release in 24 hours (Figure 1). This 
underscores the apparent high affinity of RAL for DPPC bilayers as compared to 
DOX.  
In order to form stable liposomes when using a combination of DOX and RAL in the 
same liposomal system, the concentration of each drug was reduced to 1 mM due to 
stability issues regarding liposomal aggregation. This system still failed to achieve the 
desired colloidal stability due to adsorbed DOX leading to aggregation. The 
concentration of the drugs used was further reduced to 0.5 mM which still showed 
aggregation. Hence, PL was incorporated into the liposomal bilayer in order to achieve 
stability by taking advantage of steric hindrance imparted by the PEO chains. This 
stabilized system was used for subsequent release studies, but no drug was detected in 
the dialysis or drug release media after 24 hours, suggesting complete drug 
encapsulation. It might be noted that these liposomal formulations displayed minimal 
leakage of the entrapped material, suggesting the advantage of minimal toxicity in vivo 
when using analogous formulations to entrap potent or toxic drugs with a narrow 
therapeutic index.  In the interest of developing useful drug delivery systems, and in 
light of the complete absence of drug release from these two-drug containing 
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formulation, it was hypothesized that a trigger mechanism was needed so that the 
drugs would eventually be released from these liposomes. Accordingly, MNP‟s that 
could be subjected to an external electromagnetic field (due to their paramagnetic 
property), thereby inducing vibration and heating within the lipid bilayer, were 
successfully incorporated within the liposomal bilayers. Upon exposure to this 
external electromagnetic field, the MNP‟s would be expected to produce a local 
hyperthermia within the bilayers, thereby increasing the temperature above the Tm, 
and trigger drug release. MNP-containing liposomes did not show any drug release in 
the absence of an external magnetic field. However when subjected to a 30 min 
exposure to the external electromagnetic field and then stored at 37 °C, a release 
pattern was observed. As shown in Figure 7, the samples were collected at various 
time points such as 1, 3, 4, 20, 21 and 24 hours.  
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Figure 7. Rf- induced release of DOX from liposomes at 37 °C and at pH 7.4 in 137 
mM PBS. Both DOX and RAL were encapsulated at 0.5 mM concentration.. The 
lipid: MNP ratio was 10000:1 that produced local hyperthermia and triggered the 
release of DOX. The red curve represents the drug release profile as a function of the 
RF heating cycle and the time points at which samples were collected in real time. 
 
Before the collection of each sample, the formulations were subjected to 30 min. of 
RF exposure and stored at 37 °C for another 30 min. DOX release was independent of 
time and observed only after the exposure to the RF radiation. The rate and extent of 
DOX release from the liposomes was triggered by its exposure to an electromagnetic 
field. In contrast, electromagnetic irradiation had no effect on RAL release from lipid 
vesicles.  RAL, being highly hydrophobic in nature and strongly interacting with the 
bilayer as demonstrated by NMR studies, did not show any release in vitro.  
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4. CONCLUSION 
In the current investigation, we have successfully incorporated multiple drugs in the 
liposomal bilayers by taking advantage of their disparate physical-chemical properties 
and the different regions of DPPC liposomes. This combination therapy might be used 
for the treatment of various conditions that may require multiple drug administration 
for synergistic effect and in turn improved therapy. Poor stability is a general 
observation with liposomal systems which has been addressed by the use of PL‟s via 
steric hindrance that will maintain a homogenous particle size for an enhanced period 
of time ensuring a metered uniform dose at the time of administration. When using the 
combination of DOX and RAL, in order to enhance liposome stability, the drug 
concentrations had to be reduced from 2 mM to 0.5 mM. The presence of PL, MNP‟s 
and RAL in the bilayer had a pronounced effect on the suppression of DOX release. 
Under normal physiological conditions, the minimum cargo leakage is very desirable 
phenomena as it prevents various untoward systemic toxicities. Embedding MNP‟s in 
the bilayers gives the advantage of controlling and triggering the drug release with the 
aid of a physiologically invasion free magnetic field. In vivo studies using animal 
models might be conducted in order to better understand, refine, and optimize the 
performance of these delivery systems.       
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Supplemental Information 
Calibration Curves  
1) Doxycycline HCl 
 
 
2) HPLC chromatograms: 
a) 20nM 
Area % Report 
Data File: C:\EZChrom Elite\Enterprise\Projects\Test\Data\20nM dox3-
24-2012 4-42-35 PMrkD-Rep1.met 
Method: C:\EZChrom Elite\Enterprise\Projects\Test\Method\rkD.met 
Acquired: 3/24/2012 4:45:00 PM 
Printed: 3/26/2012 1:30:52 PM 
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Chromatogram 1.  
1: 350 nm, 4 
nm Results 
    
Retention 
Time 
Area Area % Height Height % 
19.260 5260 100.00 257 100.00 
     
Totals     
 5260 100.00 257 100.00 
 
 
b) 200nM: 
Area % Report 
Data File: C:\EZChrom Elite\Enterprise\Projects\Test\Data\200nM dox3-22-2012 
10-28-04 AMrkD.met 
Method: C:\EZChrom Elite\Enterprise\Projects\Test\Method\rkD.met 
Acquired: 3/22/2012 10:30:26 AM 
Printed: 3/26/2012 2:25:21 PM 
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nm Results 
    
Retention 
Time 
Area Area % Height Height % 
19.300 89903 100.00 2688 100.00 
     
Totals     
 89903 100.00 2688 100.00 
 
c) 2000nM 
Area % Report 
Data File: C:\EZChrom Elite\Enterprise\Projects\Test\Data\2000nM dox3-
24-2012 11-12-52 PMrkD-Rep1.met 
Method: C:\EZChrom Elite\Enterprise\Projects\Test\Method\rkD.met 
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3) Raloxifene HCl 
 
4) HPLC chromatograms: 
a) 20nM 
Area % Report 
Data File: C:\EZChrom Elite\Enterprise\Projects\Default\Data\Swapnil\New 
calibration\20nM ralox in PBS5-31-2012 5-11-02 PM-Rep2.dat 
Method: C:\EZChrom 
Elite\Enterprise\Projects\Default\Method\Swapnil\Rolaxifene_03_13_11.met 
Acquired: 5/31/2012 5:13:21 PM 
Printed: 6/1/2012 9:56:01 AM 
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Retention Time Area Area % Height Height % 
6.140 18760 100.00 2347 100.00 
     
Totals     
 18760 100.00 2347 100.00 
 
b) 200nM 
Area % Report 
Data File: C:\EZChrom Elite\Enterprise\Projects\Default\Data\Swapnil\New 
calibration\200nM ralox in PBS5-31-2012 7-28-49 PM-Rep1.dat 
Method: C:\EZChrom 
Elite\Enterprise\Projects\Default\Method\Swapnil\Rolaxifene_03_13_11.met 
Acquired: 5/31/2012 7:31:10 PM 
Printed: 6/1/2012 10:06:53 AM 
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Totals     
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c) 2000nM 
Area % Report 
Data File: C:\EZChrom Elite\Enterprise\Projects\Default\Data\Swapnil\New 
calibration\2000nM ralox in PBS5-31-2012 8-43-54 PM-Rep1.dat 
Method: C:\EZChrom 
Elite\Enterprise\Projects\Default\Method\Swapnil\Rolaxifene_03_13_11.met 
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Printed: 6/1/2012 10:17:29 AM 
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ABSTRACT 
Liposomes have been used in pharmaceutical industry for over 40 years and provide 
an attractive vehicle for delivery of hydrophilic as well as hydrophobic drugs. The 
hydrophilic drugs are entrapped in the aqueous core of the liposomes and do not tend 
to interact significantly with the bilayers in terms of packing parameters, dynamics, 
and state of aggregation. However, the opposite is true for hydrophobic additives and 
advances in analytical tools provide the opportunity to analyze these interactions. In 
this study, we investigate five hydrophobic small molecules (hydrophobic and 
phenolic) and their potential interactions with the DPPC bilayers. The liposomal 
processing parameters were kept constant with an aim to analyze the effects of 
different di- or polyphenolic compounds on DPPC liposomes. Various analytical tools, 
including differential scanning calorimetry and phosphorus- and proton nuclear 
magnetic resonance spectroscopy, were employed in order to evaluate the localization 
of the drugs along the thickness of the bilayer, and their effect on bilayer 
characteristics.  It was observed that the molecules that tend to be located deep in the 
bilayers, do not assist in maintaining the hydrodynamic diameter of the vesicles as 
opposed to the drugs located in the vicinity of the glycerol region of the head group 
(within the bilayer). The molecules present in the upper region of acyl chains (C1-C10) 
prevented aggregation due to tight packing of the adjoining DPPC molecules.   
  
1. INTRODUCTION 
Liposomes have been used for a variety of applications, including therapeutics, 
diagnostics, and bioanalysis.
1
 As described by Bangham et. al., liposomes are formed 
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by the phospholipid bilayers that encapsulate aqueous phases and are  categorized as 
small unilamellar vesicles (20-100 nm), large unilamellar vesicles (50-400 nm) and 
multilamellar vesicles (400-5000 nm).
2
 These phospholipids are known to be inert, 
non-immunogenic, and possess no intrinsic toxicity.
3
 Due to the presence of both 
hydrophobic and hydrophilic domains, i.e., a bilayer and an aqueous core, liposomes 
have the capacity to encapsulate drugs, biologics, and various chemical substances of 
varying physiochemical properties within them.
4
 The lipid bilayers constitute the 
second major region of liposomes, aiding in the incorporation hydrophobic substances 
which can be administered at effective concentrations without the use of any toxic 
organic solvents or solubilizing agents.
5
 
The inclusion of hydrophobic materials has anecdotal effects on membrane dynamics 
and the phase behavior of liposomal bilayers that has been proved both experimentally 
and by molecular simulations.
6-10
 In our previous study it was noticed that raloxifene 
hydrochloride (RAL), a selective estrogen receptor modulator (having estrogenic 
actions on bone and anti-estrogenic actions on uterus and breast
11
) increased the 
transition temperature of DPPC liposomes from 43 °C to 49 °C. This observation led 
to the investigation of the effect of compounds with similar physiochemical properties 
(such as hydrophobicity and di- and polyphenolic composition) as RAL, on DPPC 
bilayer dynamics, packing and, in turn, the colloidal stability of DPPC liposomes as a 
function of time. The purpose of this work was to determine the physiochemical 
changes in the bilayer properties with the addition of various hydrophobic drugs such 
as RAL, garcinol (GAR), quercetin (QTN), trans-resveratrol (RVR) and bisphenol A 
(BPA). GAR is a polyisoprenylated benzophenone known for its antibiotic and anti-
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cancer activities.
12
 QTN and RVR are plant-derived phenolics used for a variety of 
ailments such as inflammation, viral diseases, asthma, eczema, and cancer.
13-17
 
Although BPA is a toxic compound reported to cause behavioral alterations, 
preneoplastic lesions in prostate, and mammary gland and uterus
18
, it was examined in 
this study not to serve a therapeutic but to appreciate its interaction with the DPPC 
bilayer owing to its hydrophobicity, aromatic, diphenolic character, and transoid 
conformation due to the presence of two geminal methyl groups. 
The current investigation also includes localization of the drugs in various parts of the 
lipid bilayer which was determined by thermal, electrical and magnetic analysis (i.e. 
nano- Differential Scanning Calorimetry, zeta potential and 
31
phosphorus- and proton 
nuclear magnetic resonance). Liposomes were prepared by a film rehydration 
technique and were then characterized under similar conditions for comparative 
analysis. It was observed that QTN and RVR were localized deep in the bilayer (C10-
C16 portion of acyl chains) that improved the packing properties of the chains but did 
not improve the colloidal stability. QTN and BPA were found to be associated with 
the glycerol region of the head group (C1-C10) and maintained the hydrodynamic 
radius over a period of 5 days. RAL formed larger vesicles as compared to other drugs 
but maintained the particle size and was found to be present in multiple stable 
orientations of the bilayer in the vicinity of the glycerol head groups.     
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2. MATERIALS AND METHODS 
2.1. Materials. 
1, 2-Dipalmitoyl-sn-glycero-3-phospocholine monohydrate (DPPC) was purchased 
from Corden Pharma (Colorado, USA). Quercetin (QTN) was purchased from Acros 
organics, raloxifene hydrochloride (RAL) from Fisher Scientific (Pittsburgh, PA), 
resveratrol (RVR) from CS Inc. (Danbury, CT), garcinol (GAR) from Enzo Life 
Sciences, NY and bisphenol A (BPA) from Sigma-Aldrich (St. Louis, MO). Phosphate 
buffered saline (PBS) tablets were purchased from MP Biomedicals (Solon, OH). All 
other reagents were purchased from Fisher Scientific and were of analytical grade. 
 
2.2. Liposome preparation.  
Vesicles were prepared at a 17 mM lipid concentration for all formulations. For the 
31
P-NMR, the vesicles were made in 90:10 (water: D2O), 100% D2O for 
1
H-NMR and 
137 mM PBS for dynamic light scattering (DLS), Nano- Differential Scanning 
Calorimetry (nano-DSC) and zeta potential experiments. The vesicles were prepared 
as described by Chen et al.
19
 The samples were further diluted to a lipid concentration 
of 1 mM for DLS and zeta potential, and 0.1 mM for nano-DSC using 137 mM PBS. 
Briefly, liposomes were prepared by dissolving 12.5 mg of DPPC in 1 ml of 
chloroform (for blank DPPC liposomes and GAR). Chloroform was removed by 
rotary evaporation at 50 °C (above the DPPC melting temperature) starting at 450 
mbar for 30 min, then decreased to 300 mbar for 30 min, and finally 200 mbar for 30 
min. This lipid film was kept under vacuum for 12 hours at room temperature to 
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remove traces of chloroform. It was then rehydrated with appropriate solvent for 2 
hours at 50 °C. QTN, RVR, BPA along with DPPC were dissolved in methanol 
separately due to their limited solubility in chloroform whereas for RAL liposomes, 
RAL and DPPC were dissolved in a 1:1 ratio of chloroform: methanol due to the 
insolubility of RAL in pure chloroform. The organic solvents were removed by rotary 
evaporation at 50 °C (above the DPPC melting temperature) starting at 450 mbar for 
30 min, then decreased to 300 mbar for 30 min, and finally 200 mbar for 30 min. This 
lipid film was kept under vacuum for 12 hours at room temperature to remove traces 
of organic solvents. The film was rehydrated with appropriate solvent at 50 °C for 2 
hours. The resulting aqueous dispersions were then sonicated for 1hour using a bath 
sonicator maintained at 50 °C.  
 
2.3. Nuclear Magnetic Resonance. 
All NMR data were acquired on an Agilent NMRS 500 MHz NMR spectrometer using 
a 5mm NMRone probe. The probe temperature was thermostated at 37 °C for all 
experiments. Liposome formulations analyzed by NMR were prepared as previously 
described with the exception that 10% D2O in water (
31
P-NMR) or 100% D2O (
1
H-
NMR) were used as a solvent in order to provide a deuterium lock signal. 
31
P-NMR 
data were collected at 202.3 MHz for 60 K scans with a 35.7 kHz sweep width using 
131 K data points. Acquisition time was 1.3 sec with a relaxation delay of 0.5 sec. A 
line broadening of 50 Hz was applied to all spectra. All spectra were indirectly 
referenced to H3PO4 set to 0 ppm. Data were acquired without spinning. 
1
H-NMR data 
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were collected at 499.8 MHz using the conditions defined in figure captions. All NMR 
data were processed with mnova program V8.1 Mesterlab research SL.  
 
2.4. Nano Differential Scanning Calorimetry (nano-DSC).  
Nano-DSC was performed using a TA Instruments Nano DSC (New Castle, DE, 
USA). Samples at a concentration of 0.1 mM lipid were degassed under vacuum for 
30 min before loading into a 0.6 mL capillary cell. The cell was then pressurized with 
nitrogen to 1 atm and equilibrated at 25 °C. The sample was scanned at 1 °C min
-1
 
over a range of 10 °C to 60 °C.  
 
2.5. Dynamic Light Scattering.  
DLS measurements were performed using a Malvern Instruments Zetasizer Nano ZS 
with a backscattering detector angle of 173° and a 4 mW, 633 nm He-Ne laser 
(Worcestershire, UK). For size distribution studies, 1 ml of the liposome formulations 
was analyzed in an optical grade polystyrene cuvette at 37 °C. Before analysis, the 
samples were stored at 37 °C and then analyzed after 24 hours. 
 
2.6. Zeta potential.  
A small aliquot part of each formulation (17 mM DPPC) was diluted with 137mM 
PBS to give a final lipid concentration of 1 mM. Zeta potential values were then 
determined using a laser doppler procedure with a Malvern Instruments Zetasizer 
Nano ZS at 25 °C. Air drop interference was eliminated before measuring the zeta 
potential. 
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3. RESULTS AND DISCUSSION 
In the previous chapter (in this dissertation), it was observed that RAL increased the 
Tm of DPPC liposomes significantly. It also had a pronounced effect on the 
31
P-NMR 
peak with a shoulder in the upfield region indicating shielding of the NMR signal. 
This observation initiated the current work of exploring the interactions of various 
hydrophobic di- and poly-phenolic compounds (Figure 1) using thermal and magnetic 
analysis. The effect of the incorporation and localization of these drugs in the lipid 
bilayers on the colloidal stability of DPPC liposomes is also reported. 
 
Figure 1. Chemical structures of different phenolic compounds and DPPC. 
 
3.1. Thermal analysis. 
Differential scanning calorimetry has been widely used in order to estimate the 
location of hydrophobic moieties in the liposomal bilayer as well as their interaction 
with the lipid.
20-22
 The hydrophobic interior of a lipid bilayer is anisotropic in nature 
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due to a long range order of the acyl chains, which generates from cooperative 
interactions between these polymethylene chains. A cooperative unit exists in the gel 
phase of a bilayer due to transmission of motion among the fatty acid chains that are 
packed in a highly ordered hexagonal array.
23
 The transition from gel to liquid 
crystalline phase suggests a change from nearly all trans to partially gauche 
conformation of C-C bonds in the chains.
24
 This transition is an endothermic event and 
exhibits a specific profile in the DSC curve that provides information about the 
cooperative unit undergoing phase transition. Since the probability of C-C gauche 
conformation is higher in the end region of the chain (C10 and up), the center of a lipid 
bilayer tends to be more fluid due to disorder, and the interactions in the C1-C10 region 
of the chain mainly regulate the size of the cooperative unit undergoing phase 
transition. The location of a hydrophobic molecule in different regions of the bilayer - 
phosphorylcholine, glycerol backbone, C1-C10 methylene, and C10 and up methylene- 
and its interaction with these regions affect the cooperative unit and consequently the 
peak characteristics in the DSC profile. Thus, if a hydrophobic moiety is located in the 
C1-C10 methylene region, it interacts with the cooperative unit and broadens the phase 
transition peak, whereas if it is located in the center (C10 and up methylene region) of 
the bilayer, the size of the cooperative unit is not affected and a sharper peak is 
detected. The packing of the cooperative unit can be altered in both cases, leading to 
an increase or decrease in the phase transition, which is also referred to as the melting 
temperature (Tm) of the bilayer. If a hydrophobic moiety interacts with the glycerol 
region of the bilayer, a shoulder peak is detected at a lower temperature along with the 
parent transition peak due to the formation of a new phase of its own smaller 
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cooperative units that don't coexist with the parent cooperative unit of the bilayer. On 
the other hand, a completely new peak appears due to formation of a new phase when 
chemical moieties such as cations and anions interact with the phosphorylcholine 
region of the bilayer.
25
 
As shown in Figure 2, the liposomal bilayer of blank DPPC depicted its typical sharp 
peak at about 43 °C due to transition from a gel to liquid crystalline phase.  
 
Figure 2. DSC endotherms depicting the effect of various drugs on the Tm of DPPC 
liposomes.  
 
It can be estimated that RAL was located in the C1-C10 methylene region of the bilayer 
and interacted with the parent cooperative unit, since the phase transition peak was 
slightly broadened after incorporation of RAL into the bilayer. Although the entropy 
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of this phase transition (Table 1) was only slightly increased, the enthalpy was 
substantially increased due to a significant increase in the Tm to about 49 °C. 
Formulations ΔH (Kcal/mol) ΔS [Kcal/(mol.K)] Tm (°C) 
Blank DPPC 08.43 0.1963 42.96 
DPPC + 2mM RAL 12.12 0.2463 49.24 
DPPC + 2mM RVR 13.30 0.3242 41.05 
DPPC + 2mM QTN 14.66 0.3565 41.12 
DPPC + 2mM BPA 11.68 0.2952 39.58 
DPPC + 2mM GAR 07.98 0.1917 41.62 
 
Table 1. Enthalpy, entropy, and transition temperatures of different liposomal 
formulations containing di- and polyphenolic analytes.  
Such a significant increase in the Tm due to the incorporation of RAL suggests that the 
packing of the cooperative unit was altered in such a way as to enhance the rigidity of 
the bilayer. Like RAL, GAR also exhibited a peak broadening effect, suggesting its 
incorporation into the C1-C10 methylene region as well. In the case of GAR, however, 
the entropy, enthalpy, and the Tm were slightly decreased as compared to control, 
suggesting a slight reduction in the bilayer rigidity. A slight reduction in the Tm, 
broadening of the transition peak, and the appearance of a small shoulder at the lower 
temperature suggests that BPA was located in between the glycerol and the C1-C10 
methylene region and strongly interacted with the glycerol groups of DPPC molecules. 
Although the incorporation of RVR and QTN also depicted a slight reduction in the 
Tm, no peak broadening was detected, suggesting that the location of these drug 
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molecules was in the center (C10-C16 methylene region) of the bilayer. Since the 
concentration of all of the polyphenolic compounds that were used in this work was 
relatively high (2 mM), it can be estimated that the center region of the bilayer could 
have been saturated with the drug in the case of both RVR and QTN. Consequently, it 
may have increased the cooperativity of phase transition leading to a sharpening of the 
transition peak and an increase in the entropy and enthalpy of phase transition. 
 
3.2.  31P-NMR. 
The effect of incorporating RVR, RAL, QTN, BPA and GAR into DPPC liposomes 
was also illustrated by 
31
P-NMR, as shown in Figure 3.  
 
Figure 3. 
31
P-NMR spectra after 60K scans at 37 °C in (9:1) water: D2O as solvent, 
characterizing the interactions of the phenolic analytes with the phosphate head groups 
of DPPC liposomes. 
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With a blank DPPC liposome, one single sharp peak was obtained, a characteristic 
indicator of small, unilamellar vesicles.
26
 The presence of small, unilamellar vesicles 
was also confirmed with cryo-TEM imaging (data not shown). With the addition of 
QTN to DPPC liposomes, no chemical shift was observed; however, the line shape 
broadened slightly. This peak broadening was unlikely to be caused by larger vesicles 
in solution because of the constant experimental procedure which produces 
morphologically similar liposomes (as indicated by DLS data). Thus, it is evident that 
there is a dynamic process involved with the phosphate head groups in the presence of 
QTN. However, the DSC data suggest that QTN is located deep in the bilayer, a 
situation that improves the orderliness of the acyl chains as it sharpens the transition 
peak. The NMR peak broadening is thus observed as an indirect effect on the change 
in the environment of the phosphate head groups due to an increase in the orderliness 
of the acyl chains and sharpening of the DSC curve. With the incorporation of RAL 
and BPA, an additional resonance appears upfield of DPPC resonance due to shielding 
and increased exposure of the phosphate groups. This upfield resonance is a result of 
additional shielding due to the rigid aromatic rings of RAL and BPA, which may 
orient themselves in the lipid bilayers in the proximity of the phosphate head groups. 
In addition, BPA has a shoulder at a lower temperature in the DSC curve and a peak 
broadening effect similar to RAL, suggesting localization of both the drugs in the 
vicinity of the glycerol moiety in the C1-C10 chain region. GAR showed a similar 
effect with a much broader peak. This might be attributed to multiple stable 
interactions with the phosphate head groups. On the other hand, RVR showed the 
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broadest peak, which again indicates multiple stable interactions with the head group. 
However, RVR, like QTN, was presumed to be present deep in the bilayer at C10-C16 
region. Thus, there was no direct correlation between the DSC data and the NMR peak 
broadening, which might be due to the RVR-induced increase in the orderliness of the 
bilayers that in turn affect the phosphate head group environment. The orientation of 
different chemical species in various domains of liposomal bilayer was thus proposed. 
  
3.3.  1H-NMR. 
All resonances in the blank DPPC liposome spectrum are broadened, consistent with 
the formation of vesicles. These results are consistent with general NMR principles 
and previous observations of vesicles.
27,
 
28
 In this study, the phospholipid glycerol 
resonances were not observed. In the case of BPA, the glycerol methine resonance 
becomes clearly observable in liposomes loaded with BPA, as seen in Figure 4.  
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Figure 4. 1D 
1
H-NMR spectra of RAL, BPA and blank DPPC liposomes showing 
aromatic peaks from the drug molecules.  
 
The decreased line width is obtained because of an increase in local molecular motions 
in that region of the phospholipid. This would suggest that BPA is bound near the 
head group region. Also observed were the aromatic resonances of BPA in the NMR 
spectrum at 7.12 ppm (2, 6 and 2‟, 6‟) and at 6.84 ppm (3, 5 and 3‟, 5‟). All of the 
aromatic resonances are broadened, which is indicative of the entrapment of BPA in 
the hydrophobic vesicle wall.
29
 The BPA methyl resonance was not identified in the 
spectrum because of the overlapping DPPC resonances. In Figure 5(b), additional 
NOE are observed between the BPA resonance at 6.84 ppm and the -N(CH)3 of the 
choline and a methylene near the carbonyl moiety of the acyl chains. This further 
supports the localization of BPA to near the glycerol region.  
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Figure 5. 2D 
1
H-NMR spectra of (a) RAL and (b) BPA containing DPPC liposomes. 
 
In the case of RAL (Figure 4), the vesicle resonances are similar to those observed for 
BPA-loaded vesicles. Aromatic drug resonances are observed with broadened line 
widths indicative of incorporation into the vesicles. The DPPC resonances are sharper 
in RAL-containing liposomes as compared to those observed in blank DPPC 
liposomes. The observed aromatic protons integrate to more than the expected value 
for one species of RAL. Assigning a value of one proton to the smallest aromatic 
resonance gives a total proton count of approximately 22, which is double the 
expected proton count for RAL. A possible explanation for this observation is that 
RAL is binding to the vesicle in two different ways which are not inter-converting on 
the NMR time scale. From Figure 5(a) we see more than the expected number of 
aromatic to aromatic NOE‟s in the 2D NOESY of RAL-containing liposomes. In bulk 
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solvent, RAL would be expected to exhibit three aromatic to aromatic NOE‟s. Two 
NOE‟s would arise from the protons of the two p-substituted phenyl rings and would 
be twice the intensity of the NOE between the ortho- protons of the benzothiophene 
ring of RAL. In RAL-containing liposomes we see NOE‟s for 5 aromatic to aromatic 
interactions and, while these interactions have not been assigned, it would seem 
unlikely they are all intramolecular NOE‟s, and some of the cross peak may represent 
exchange between multiple orientations of RAL in the vesicle wall environment. We 
also observe NOE‟s from two of the aromatic resonances to the N-methyl resonance of 
the choline head group (indicated by black arrow).  
A single, broad aromatic resonance was observed in both the 1D and 2D data collected 
for RVR (data not shown). No resonances from GAR were observed in either 1D or 
2D data collected. This indicates GAR and RVR are binding very tightly within the 
vesicle wall. Evidence of binding is seen because the -CH2 and -CH3 resonances from 
DPPC are sharper in GAR- and RVR-containing liposomes as compared to blank 
DPPC controls. This effect is similar to the other polyphenolics used in the study. In 
the case of QTN, five broadened aromatic peaks consistent with QTN structure are 
observed (Figure 6).  
 53 
 
 
Figure 6. 1D 
1
H-NMR spectra of (1) blank and (2-10) QTN-containing DPPC 
liposomes. No aromatic peaks were seen in blank DPPC liposomes whereas QTN 
peaks sharpened with the application of heat due to increased molecular mobility. 
 
Again, the peak broadening indicates QTN binding to the vesicle wall. Also seen were 
changes in the DPPC spectrum indicative of drug binding. The -CH2 and -CH3 peaks 
are sharpened, as was observed with other phenolics assessed in this study. Also seen 
is a sharpened glycerol methine resonance as further proof of binding. The aromatic 
peaks observed were very broad. It was hypothesized that above the Tm of these 
vesicles, the molecular motion of QTN in the vesicle wall would increase, which could 
be indicated by sharper peaks. Thus, the formulations were heated from 38 °C to 45 
°C (the Tm of QTN containing liposome was 41.12 °C) at 1 °C increments (10 min 
temperature equilibration time) and 1D NMR spectra were collected after each 
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temperature increment. Throughout the experiment, there was no significant chemical 
shift change for QTN resonances, indicating a consistent molecular environment. All 
five QTN resonances sharpened slightly in appearance as the temperature increased, a 
phenomenon indicative of increased molecular motion in the vesicle wall. As the 
temperature increased, sharp resonances consistent with QTN in bulk D2O were also 
observed. The intensity of these resonances increased with increasing temperature, 
which suggests release of QTN from the vesicle wall into bulk solvent. 
     
3.4. Particle size and zeta potential analysis: 
The particle size analysis was conducted by DLS in triplicate over a period of time 
until aggregation was observed within the liposomes over a period of five days. As 
seen in Figure 7, several formulations maintained relatively consistent particle size 
save those containing QTN and RVR.  
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Figure 7. Liposome size (in nm) measured by DLS at 37 °C over a period of 5 days, 
indicating aggregation only with QTN- and RVR-containing DPPC liposomes.  
It is evident that despite their effect on increasing the orderliness of the acyl chains of 
DPPC, QTN and RVR could not maintain the particle size and to the liposomes 
containing these compounds underwent aggregation. Thus, the localization of these 
and perhaps other hydrophobic compounds deep into the bilayer can have a significant 
effect on the stability of liposomes. In contrast, RAL, GAR, and BPA (located in the 
vicinity of the head group or C1-C10 chain segment of DPPC) do not tend to alter the 
colloidal stability of liposomes which was evident from particle size data.   
Zeta potential measurement was used to quantify the extent of external phosphate 
group exposure of liposomes in the presence of the phenolic compounds by measuring 
the surface charge. The zeta potential of blank DPPC liposomes over a period of 5 
days was -2 ± 1 meV, which is consistent with the literature due to the adsorption of 
 56 
 
OH
-
 ions from the surrounding buffer and exposure of the phosphate head groups.
30
  
The zeta potential of GAR-containing liposomes was -11 ± 2 meV over a period of 5 
days, which could be attributed to the localization of the large GAR molecules in the 
vicinity of head group and increasing the exposure of phosphate head groups to the 
external media. This explains the DSC peak broadening effect of GAR due to a 
decrease in the cooperativity of mixing and its localization at the C1-C10 region of the 
DPPC acyl chains. QTN and RVR were present deep into the bilayers while RAL and 
BPA might have aligned linearly with the acyl chains. Thus QTN, RVR, RAL and 
BPA did not have a significant change in the zeta potential of the liposomes. The zeta 
potential for these formulations was -1 ± 2 meV for a period of 5 days and was 
consistent for the mentioned period of time.  
 
4. CONCLUSIONS 
The localization of hydrophobic phenolics in DPPC liposomes was successfully 
characterized using a variety of analytical techniques. It has been demonstrated that 
the addition of various hydrophobic phenolics to liposomes may profoundly affect the 
characteristics of the vesicles and the bilayer organization. Despite certain similar 
physiochemical properties, these phenolics vary in geometry, flexibility, and 
molecular weight, and thus may be located in different regions (or even stable multiple 
positions as seen in the case of RAL) throughout the phospholipid bilayer. The 
phenolic compounds that were shown to be located deep in the bilayer do not appear 
to affect the colloidal stability of the liposomes.  
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SUPPLEMENTARY INFORMATION 
1) Phenolics in bulk solvents (1H-NMR) 
 
Spectra 1. DPPC in CDCl3 
 
Spectra 2. BPA in MeOD 
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Spectra 3. GAR in CDCl3 
 
Spectra 4. QTN in MeOD 
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Spectra 5. RAL in CDCl3:MeOD (1:1) 
 
Spectra 6. RVR in MeOD 
 
 
 60 
 
2) Phenolics in vesicles 
 
Spectra 1. RVR in DPPC 
 
Spectra 2. GAR in DPPC 
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ABSTRACT 
In this study, gemcitabine was combined with the cyclooxygenase-2 inhibitor 
celecoxib in DPPC liposomes and assayed in vitro in order to assess the potential of 
these combination liposomes for the treatment of pancreatic cancer. Drug release from 
the liposomes was also controlled by an alternating high frequency AC magnetic field. 
Due to presence of hydrophobic iron oxide nano particles in the vesicular bilayer, 
local hyperthermia is produced that converts the rippled gel phase of liposomes to 
liquid crystalline phase.  It was hypothesized that this phenomenon would induce the 
controlled release of these synergistic drugs from the liposomes. The liposomes were 
characterized in terms of drug localization by differential scanning calorimetry and 
31
P-nuclear magnetic resonance spectrometry. Liposome morphology and size were 
confirmed by cryo-TEM and dynamic light scattering and remained in the sub-micron 
size range throughout the study. The MTT assay was performed in the human 
pancreatic cancer cell line BxPC-3 in order to assess cell viability. The results of the 
study indicated that liposomes containing both the drugs were more cytotoxic than 
single drug containing liposomes. 
 
1. INTRODUCTION 
According to the American Cancer Society, pancreatic cancer is the tenth most 
common cancer diagnosed in men and ninth most in women in the United States. An 
expected 45,420 new cases will be diagnosed in the United States of whom 39,590 
will die in 2014
1
, with a 5 year survival rate of 6%. Tumoral hypoxia (expression of 
hypoxia inducible factor -1) that correlates with an aggressive tumor phenotype and, in 
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turn, the development of chemoresistance, makes the treatment of certain pancreatic 
cancers particularly difficult.
2, 3
 Gemcitabine (GEM), which is a first line of treatment 
for advanced pancreatic cancer, shows only moderate benefits due to chemoresistance 
that might be either intrinsic or acquired.
4, 5
 However, the definitive underlying 
mechanism for GEM resistance in pancreatic cancer is unclear and maybe associated 
with atypical cell signaling pathways which are responsible for modulation in the cell 
cycle that leads to apoptosis of cancer or the inhibition of the conversion of GEM to 
its active form.
6-10
 It has also been observed that there is an overexpression of 
cyclooxygenase 2 (COX-2) in more than 75% of invasive ductal carcinomas, which 
includes tumorigenesis of the pancreas.
11-17
  Thus, the inhibition of COX-2 may be a 
complementary therapeutic target along with traditional anticancer therapies in 
pancreatic cancer.  
Since the use of a single drug such as GEM through systemic administration has 
not produced satisfactory results in terms of tumor treatment, the use of multiple drugs 
should be given a high priority. The overexpression of COX-2 in pancreatic cancer 
and its interference with tumor angiogenesis provides an interesting rationale for using 
a combination of a COX-2 inhibitor such as celecoxib (CEL) with chemotherapeutic 
agent, such as GEM, in order to achieve much greater therapeutic efficacy.
18
 A Phase 
II clinical trial of this combination has been proved to be effective, safe, and less toxic 
while treating the patients with advanced pancreatic cancers.
19
 
For the above mentioned combination therapy, the dosage regimen includes oral 
CEL twice daily for 28 days and intra venous (IV) GEM for 65 minutes on days 1, 8 
and 15.
20
 This is mainly attributed to the difference in the physiochemical properties 
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of the drugs. CEL belongs to BCS class II with a low aqueous solubility of 5 µg/ mL 
and has a dissolution rate inhibited oral bioavailability of 22%.
21
 On the other hand, 
GEM  is a BCS Class I drug with an aqueous solubility of 83 mg/mL with a short 
plasma half-life of 45 minutes.
22
 Also, an IV dose of GEM can produce various 
systemic side effects causing a hindrance in the treatment.
23
 In order to overcome 
these various untoward effects, concurrent controlled delivery of these therapeutic 
agents is necessary. The synergistic combination of two drugs may reduce the toxicity 
of a single large dose of one drug whereas the second drug may maintain or improve 
desired therapeutic efficacy.  
Liposomes are a promising tool for the concurrent delivery of multiple drugs 
owing to their ability to carry a drug payload in either the aqueous core (perhaps for 
hydrophilic GEM) or the lipid bilayer (for hydrophobic CEL).
24
 In order to trigger the 
release of the liposomal contents, super paramagnetic iron oxide nano-particles 
(biocompatible and unreported in vivo toxicity) embedded in the liposomal bilayer are 
reported to cause local hyperthermia with the application of an alternating AC 
magnetic field.
25-27
   
In this investigation, a synergistic combination of GEM and CEL was loaded into 
1, 2-dipalmitoyl-sn-glycero-3-phospocholine monohydrate (DPPC) liposomes in order 
to evaluate the applicability of these nano devices to deliver multiple drugs. Oleic acid 
capped iron oxide nanoparticles (MNP‟s) were embedded within the liposomal 
bilayers for controlling the release of the cargo via the application of an 
electromagnetic field. These systems were tested in vitro in BxPC-3 (pancreatic cancer 
cell lines). It was observed that CEL potentiates the apoptotic effect of GEM (minimal 
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cell viability with the combination therapy) and the release of these drugs can be 
controlled from the liposomes using high frequency AC magnetic field.              
        
2. MATERIALS AND METHODS 
2.1. Materials. 1, 2-Dipalmitoyl-sn-glycero-3-phospocholine monohydrate (DPPC) 
was purchased from Corden Pharma (Colorado, USA). 1, 2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) was purchased from Avanti Polar Lipids, Inc., (Alabama, 
USA).Gemcitabine hydrochloride (GEM) and Celecoxib (CEL) were purchased from 
Fisher Scientific (Pittsburgh, PA). Cellulose membranes (Spectra/Por MW cutoff 3500 
Da), used for dialysis and drug release tests, were obtained from Spectrum 
Laboratories, Inc. (Houston, TX). Phosphate buffered saline (PBS) tablets were 
purchased from MP Biomedicals (Solon, OH). SPIO maghemite nanoparticles (5 nm, 
24 mg ml
-1
 or 187.9 mM Fe2O3) dispersed in chloroform were purchased from Ocean 
Nanotech (Springdale, AR). On the basis of the density of maghemite (4.9 g cm
-3
), 24 
mg ml
-1 
is equivalent to 1.43×10
17 
particles ml
-1
. All other reagents were purchased 
from Fisher Scientific and were of analytical grade. 
 
2.2. Liposome preparation. Vesicles were prepared at a 17 mM lipid concentration 
for all formulations. For the 
31
P-NMR, the vesicles were made in 90:10 (water: D2O). 
The samples were further diluted to a lipid concentration of 5.6 mM for TEM, 1 mM 
for DLS and zeta potential, and 0.1 mM for nano-DSC. The procedure was same for 
all the formulations except for the step in which various components were added was 
differed for different formulations. GEM- containing liposomes were prepared by 
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dissolving 50 mg of DPPC in 4 ml of chloroform. Chloroform was removed by rotary 
evaporation at 50 °C (above the DPPC melting temperature) starting at 450 mbar for 
30 min, then decreased to 300 mbar for 30 min, and finally 200 mbar for 30 min. This 
lipid film was kept under vacuum for 12 hours at room temperature to remove traces 
of chloroform. It was then rehydrated with GEM in 137 mM PBS for 1 hour at 50 °C. 
CEL-containing liposomes were analogously prepared. CEL and DPPC were 
dissolved in chloroform. The organic solvent was removed by rotary evaporation at 50 
°C (above the DPPC melting temperature) starting at 450 mbar for 30 min, then 
decreased to 300 mbar for 30 min, and finally 200 mbar for 30 min. This drug-lipid 
film was kept under vacuum for 12 hours at room temperature to remove traces of 
organic solvent. The film was rehydrated with 137 mM PBS. The magnetic nano-
particles (MNP‟s), CEL and GEM containing liposomes were prepared in a similar 
way by adding the MNP‟s [lipid/MNP (L/N) ratios of 5000:1 and 10000:1] to the 
organic solvent mixture containing lipid and CEL and following the film formation as 
described above using rotary evaporator and rehydrating the film with GEM in 137 
mM PBS. The resulting aqueous dispersions were then sonicated for 1 hr using a bath 
sonicator at 50 °C.  
 
2.3. Cryogenic Transmission Electron Microscopy (Cryo-TEM). Cryo-TEM 
samples were prepared at 25 °C using a Vitrobot (FEI Company), which is a PC-
controlled robot for sample vitrification. Quantifoil grids were used with 2 μm carbon 
holes on 200 square mesh copper grids (Electron Microscopy Sciences, Hatfield, PA). 
Samples were first equilibrated within the Vitrobot at 25 °C and 100% humidity for 30 
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min. After immersing the grid into the sample, it was then removed, blotted to reduce 
film thickness, and vitrified in liquid ethane. The sample was then transferred to liquid 
nitrogen for storage. Imaging was performed in a cooled microscopy stage (Model 
915, Gatan Inc., Pleasanton, CA) at 200 kV using a JEOL JEM-2100F TEM (Peabody, 
MA). 
 
2.4. Energy dispersive X-ray scattering (EDS). EDS (Model INCAx-act, Oxford 
Instrument, K) was used to detect elemental iron from the magnetic nanoparticles 
within the iron oxide nanoparticle-loaded liposomes. EDS was conducted during 
cryogenic imaging with 158 s of live time and 92 s of dead time. 
 
2.5. 
31
Phosphorus- Nuclear Magnetic Resonance (
31
P-NMR). The 
31
P-NMR spectra 
were acquired on an Agilent NMRS 500 NMR spectrometer operating at 202.3 MHz 
using a 5mm NMRone probe. The probe temperature was thermostated at 37 °C for all 
experiments. Liposome formulations analyzed by NMR were prepared as previously 
described with the exception that 10% D2O in water was used as a solvent in order to 
provide a deuterium lock signal. NMR data were collected for 60 K scans with a 35.7 
kHz sweep width using 131 K data points. Acquisition time was 1.3 sec with a 
relaxation delay of 0.5 sec. The data were processed with mnova program V8.1 
Mesterlab research SL. A line broadening of 50 Hz was applied to all spectra. Data 
were acquired without spinning. 
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2.6. Nano Differential Scanning Calorimetry (nano-DSC). Nano-DSC was 
performed using a TA Instruments Nano DSC (New Castle, DE, USA). Samples at a 
concentration of 0.1 mM lipid were degassed under vacuum for 30 min before loading 
into a 0.6 mL capillary cell. The cell was then pressurized with nitrogen to 1 atm and 
equilibrated at 25 °C. The sample was scanned at 1 °C min
-1
 over a range of 25 °C to 
60 °C.  
 
2.7. High Performance Liquid Chromatography (for quantification of 
dissolution). The HPLC system comprised a Hitachi La Chrome Elite equipped with a 
PDA detector and an automatic injector with a loop volume of 0.1 ml. For GEM 
quantification, a Phenomenex Nucleosil 10µ C18 100A (4.6 x 250 mm) column was 
used. The mobile phase consisted of 40 mM ammonium acetate/ acetonitrile (95/5) 
with a final pH of 5.5. The flow rate was 1 ml min
-1
 with an injection volume of 90 µl 
and a detection wavelength of 268 nm. The limit of detection of GEM using this 
method was 20 nM. The calibration curve in PBS was R
2 
= 0.999. The column used 
for CEL quantification was an Atlantis dC18 3µm (150 x 4.6 mm) with a mobile phase 
comprising methanol/ water (72/28). The flow rate was 1 ml min
-1
 with an injection 
volume of 90 µl and a detection wavelength of 251 nm. The limit of detection was 20 
nM and the calibration curve in PBS was R
2
 = 0.9997. The R
 2 
linearity gives a 
correlation between the concentration of drug and the area under the curve of the 
HPLC chromatogram. R
2 
value of 0.999 over a range of 20 nM to 200,000 nM 
suggests accurate quantification of drug derived from corresponding HPLC 
chromatograms.  
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2.8. Dynamic Light Scattering. DLS measurements were performed using a Malvern 
Instruments Zetasizer Nano ZS with a backscattering detector angle of 173° and a 4 
mW, 633 nm He-Ne laser (Worcestershire, UK). For size distribution studies, 1 ml of 
the liposome formulations was analyzed in an optical grade polystyrene cuvette at 37 
°C.  
 
2.9. Dialysis. The dialysis experiments were conducted at room temperature (25 ± 0.5 
°C) using 3.5 kDa tubular cellulose acetate membranes for 24 hours in 137 mM PBS 
with constant stirring and replacement of the dissolution media. The dissolution media 
was collected and analyzed by HPLC for unencapsulated drug in order to calculate the 
drug loading capacity of the liposomes.  The experiments were carried out at 24 ± 0.5 
°C and a pH of 7.4 with a stirring speed of 75 rpm using a 0.5 inch magnetic stirrer. 
Fresh media was replaced after the sampling was done at regular time intervals in 
order to maintain a sink condition. 
 
2.10. Cell line study and MTT assay. BxPC-3 cells were incubated at 37 °C under a 
humidified atmosphere with 5% CO2 and 95% air in RPMI 1640 medium (Gibco, 
USA), 10% Fetal Bovine Serum (FBS) (Gibco, USA) with 50 units per ml penicillin 
and 50 µg/mL streptomycin. The cells were seeded in a 24 well plate at optimum 
confluence (5 x 10
4 
cells/ well). Two different plates were prepared at the same time 
under similar conditions and loaded with similar liposomal formulations. One plate 
was subjected to RF heating using pancake-style copper heating coil (3 turns) and 
heating was conducted using a 1kW HotShot (Amerithem Inc., Scottsville, NY) 
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operating up to 250 A and 170 kHz. The RF exposure was conducted at 4, 8, 20, 24, 
28 and 40 hours for 30 minutes each. The other plate was left at room temperature 
outside the incubator (control) for the same amount of time as the plate subjected to 
RF heating. The cell viability was evaluated by MTT assay. Briefly, 100 µl MTT 
solution was added into each well of the 24-well plate.  Gently the plate was stirred on 
a shaking platform at 150 rpm for 5 min, and returned to the incubator.  After 3 h, 
MTT containing medium was removed and the fromazan was dissolved in 500 µl 
dimethyl sulfoxide (DMSO), and gently stirring the plate on the shaking platform for 5 
minutes. The plate was then placed in the plate reader and absorbance was measured at 
570nm and 690 nm. The background absorbance at 690 nm was subtracted from the 
reading at 570 nm to get the net absorbance value for each well.  
  
3. RESULTS AND DISCUSSION 
3.1. Morphological characterization: 
Characterization of the vesicles in terms of morphology and elemental analysis 
was essential to evaluate the effect of two drugs viz. GEM and CEL and MNP‟s on 
their size, shape, and contents. In order to confirm the inclusion of MNP‟s in the 
bilayers of the vesicles (L/N ratio was 10,000: 1), an EDS scan was performed in areas 
that had liposomes and no prevalent MNP aggregates.  
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Figure 1. EDS scan (a) conforming presence of iron oxide in the liposomes. Cryo-
TEM images (b, c and d) indicating morphology of liposomes and showing melting at 
the bilayer. The scale bar is 200 nm.  
Figure 1(a) shows distinct iron peak at 6.4 keV (Kα) and 6.9 keV (Kβ) confirming the 
presence of MNP‟s in the bilayers. No iron peaks were seen in the formulations not 
containing MNP‟s (data not shown). As seen in Figure 1(b), inclusion of the drugs and 
MNP‟s did not affect the morphology of the liposomes. Small unilamellar vesicles 
with a vesicle wall thickness of 5 nm were distinctly observed. After 1 minute 
exposure to the electron beam, the film starts melting at the bilayers as seen in Figure 
1(c) which has a high concentration of MNP‟s. On continuous exposure for one more 
minute, the film starts melting with distinct bubbles at the bilayers as seen in Figure 
1(d). Thus, it was confirmed that small unilamellar vesicles containing two drugs and 
MNP‟s were successfully formulated.  
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3.2. Drug-lipid interactions: 
The drug-lipid interactions were thermally analyzed using Differential Scanning 
Calorimetry (nano-DSC) and magnetically by phosphorus- nuclear magnetic 
resonance (
31
P-NMR) spectrometry. The concentrations of individual drugs in these 
experiments were kept higher than those in the cell line study for ease of 
quantification. As seen in Figure 2, blank DPPC liposomes show a sharp transition 
temperature (Tm) at 43 °C. This transition corresponds to the conversion of the rippled 
gel phase of the liposomal bilayers into the liquid crystalline phase.   
 
Figure 2. Nano-DSC thermographs indicating the presence of CEL and MNP‟s in the 
liposomal bilayer evident from peak broadening and shouldering corresponding to 
increased cooperativity of mixing and alteration in the bilayer packing.   
 
 76 
 
Upon the addition of 2mM GEM, the peak sharpened slightly and the Tm moved towards 
left on the temperature scale. This could be due to partitioning of some GEM into the 
bilayer despite its hydrophilicity. The peak sharpening effect is attributed to the 
localization of the drug (GEM in this case) in the much disordered C10 to C16 
methylene region of the DPPC i.e. the centre of the bilayer.
28
 Since it did not appear to 
interact with the much more ordered C1-C10 chain of DPPC, it did not affect the shape 
of the curve significantly. However, this effect is evident with the addition of 
hydrophobic CEL and oleic acid coated MNP‟s. The peak broadening effect was a 
function of concentration of the hydrophobic content in the bilayer (2mM CEL 
formulation had a broader peak than 1mM CEL). This phenomenon could be 
attributed to the interaction of the drugs and hydrophobic MNP‟s with ordered C1-C10 
region of the lipid chain resulting in the decrease in the cooperativity of mixing.  
The localization of the drugs in different domains of the liposomes was also 
demonstrated by 
31
P-NMR (Figure 3).  
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Figure 3. 
31
P-NMR spectrum indicating presence of CEL in the vicinity of the 
phosphate head groups as evidenced by the additional resonance seen in the upfield 
region. 
 
In the case of blank DPPC liposomes, a single, sharp peak characteristic of small 
unilamellar vesicles is seen (confirmed by TEM). 
29
 There was no evident change in 
the shape or location on the X-axis (indicator of chemical shifts) for GEM containing 
liposomes. This suggests that GEM did not interact with the phosphate head group 
region and hence did not alter the environment. However, with the addition of CEL, an 
additional resonance was observed in the upfield region of the spectra. This might be 
due to increased exposure of the phosphate head groups to the surrounding media. The 
additional resonance is an effect of the shielding due to the presence of aromatic rings 
of CEL in the vicinity of phosphate head groups
30
. 
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3.3. Cell line study. 
In order to evaluate the cytotoxicity of the combination of drugs, various formulations 
were prepared that were incubated with BxPC-3 cells for 48 hours with and without 
the magnetic RF heating. The results of the MTT assay suggest that there was no 
significant difference in the cell viability with or without the application of the 
magnetic field when the combination of drugs was loaded in the liposomes. As seen in 
Figure 4, at 17 mM DPPC concentration, using 3 different volumes of the 
formulations, the cytotoxicity increased with the increase in the loading volume of 
liposomes. These results suggest that at higher drug concentrations, RF heating did not 
provide a useful tool as the drug release was mainly governed by concentration 
gradient across the bilayer. Also, it was assumed that higher MNP concentration (L/N 
ratio of 5,000: 1) might have produced leaky liposomes that released the drugs without 
the application of RF heating.  
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Figure 4. BxPC-3 cytotoxicity after 48 hours incubation and RF exposure at 4, 8, 20, 
24, 28 and 40 hours for 30 minutes each. The incubated formulation contained 1) 
0.5mM Gem + 0.5mM Cel + MNP (5000:1) with volumes of 20 µL (a), 50 µL (b) and 
100 µL (c). (n=4, ± SD) 
 
In order to overcome this issue, the same formulation was loaded with a lower MNP 
content (L/N ratio of 10,000: 1). As seen in Figure 5, a very less effect was seen with 
and without the application of RF heating. There was no statistically significant 
difference in the cell viability. 
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Figure 5. BxPC-3 cytotoxicity after 48 hours incubation and RF exposure at 4, 8, 20, 
24, 28 and 40 hours for 30 minutes each. The incubated formulation contained: 
2] 0.5 mM Gem + 0.5mM Cel + MNP (10000:1) 
3] 5 µM Gem + 0.25 mM Cel +MNP (10000:1) - 17mM DPPC 
4] 5 µM Gem + 0.25 mM Cel +MNP (10000:1) - 1:1 DPPC/DOPC wt/wt 
5] 5 µM Gem + 0.25 mM Cel +MNP (10000:1) - 16mM DOPC 
(n=4, ± SD) 
 
In order to overcome the issue of concentration-driven drug diffusion from the 
vesicular bilayer, the GEM concentration was reduced to 5 µM while CEL 
concentration was kept at 0.5 mM as from our previous study it was seen that the 
hydrophobic drug RAL did not get released to a large extent from the bilayer despite 
of RF heating. Liposomes made of pure DPPC, 1:1 wt/wt of DPPC and 1,2-dioleoyl-
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sn-glycero-3-phosphocholine (DOPC) lipid and pure DOPC were made for this 
experiment. As it can be seen from Figure 5 (5-3, 5-4 and 5-5), RF heating did not 
have a significant effect on the release of GEM or CEL (qualitatively determined by 
cell viability assay). The liposomes made from pure DOPC lipid showed maximum 
cell toxicity probably due to the unsaturated acyl chains that produce leaky liposomes. 
Finally, liposomes made with a reduced lipid concentration (10 mM DPPC) and low 
drug concentration of 5 µM GEM and 0.5 mM CEL were made with MNP (L/N ratio 
10,000: 1). Three different volumes of formulations were incubated with the cells and 
similar studies were performed. It is evident form Figure 6 that the cell toxicity was 
the same with or without the application of RF heating.    
 
Figure 6. BxPC-3 cytotoxicity after 48 hours incubation and RF exposure at 4, 8, 20, 
24, 28 and 40 hours for 30 minutes each. The incubated formulation contained 6) 5µM 
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Gem + 0.5mM Cel + MNP (10000:1) - 10mM DPPC with volumes of 20 µL (a), 50 
µL (b) and 100 µL (c). (n=4, ± SD) 
 
4. CONCLUSION. 
It was observed that small hydrophilic molecule such as GEM was released from the 
liposomes containing CEL and MNP‟s irrespective of the application of magnetic 
field. This might be due to passive diffusion of GEM across the bilayer driven by a 
concentration gradient. Further study is necessary in order to optimize these liposomal 
formulations for better control of triggered release using magnetic field. 
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SUPPLEMENTAL INFORMATION. 
1) GEM calibration curve. 
 
2) HPLC chromatograms. 
a) 20 nM 
Area % Report 
 
Data File: C:\EZChrom 
Elite\Enterprise\Projects\Default\Data\20nM_PBS_Gem4-2-20134-44-36 
PMGemcetabine.met 
Method: C:\EZChrom 
Elite\Enterprise\Projects\Default\Method\Swapnil\Gemcetabine.met 
Acquired: 4/2/2013 4:45:48 PM 
Printed: 4/3/2013 9:49:40 AM 
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Minutes
0 1 2 3 4 5 6 7 8 9 10
m
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-1
0
1
m
A
U
-2
-1
0
1
6
.1
1
3
Multi-Chrom 1 (1: 268 nm, 4 nm)
20nM_PBS_Gem
Retention Time
 
Chromatogram 1. 
 
1: 268 nm, 4 
nm Results 
    
Retention 
Time 
Area Area % Height Height % 
6.113 6776 100.00 512 100.00 
     
Totals     
 6776 100.00 512 100.00 
 
b) 200 nM 
Area % Report 
Data File: C:\EZChrom Elite\Enterprise\Projects\Default\Data\200 
nM_PBS_Gem4-2-2013 4-55-53 PMGemcetabine.met 
Method: C:\EZChrom 
Elite\Enterprise\Projects\Default\Method\Swapnil\Gemcetabine.met 
Acquired: 4/2/2013 4:57:04 PM 
Printed: 4/3/2013 9:48:34 AM 
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Chromatogram 2.  
1: 268 nm, 4 nm 
Results 
    
Retention Time Area Area % Height Height % 
6.167 30071 100.00 2138 100.00 
     
Totals     
 30071 100.00 2138 100.00 
 
c) 2000 nM 
Area % Report 
 
Data File: C:\EZChrom Elite\Enterprise\Projects\Default\Data\2000 
nM_PBS_Gem4-2-2013 5-07-17 PMGemcetabine.met 
Method: C:\EZChrom 
Elite\Enterprise\Projects\Default\Method\Swapnil\Gemcetabine.met 
Acquired: 4/2/2013 5:08:28 PM 
Printed: 4/3/2013 9:46:15 AM 
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Chromatogram 3. 
1: 268 nm, 4 
nm Results 
    
Retention 
Time 
Area Area % Height Height % 
6.173 135703 100.00 9356 100.00 
     
Totals     
 135703 100.00 9356 100.00 
 
3) CEL calibration curve 
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4) HPLC chromatograms. 
a) 20 nM 
Area % Report 
Data File: C:\EZChrom 
Elite\Enterprise\Projects\Default\Data\Swapnil\Celecoxib\20nM_PBS_2 
Cel4-2-2013 3-35-11 PMCelecoxib.met 
Method: C:\EZChrom 
Elite\Enterprise\Projects\Default\Method\Swapnil\Celecoxib.met 
Acquired: 4/2/2013 3:36:23 PM 
Printed: 4/2/2013 4:42:06 PM 
Minutes
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Chromatogram 1. 
 
 
1: 251 nm, 4 
nm Results 
    
 
 
 
 
Area Area % Height Height % 
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Retention 
Time 
6.720 1821 100.00 244 100.00 
     
Totals     
 1821 100.00 244 100.00 
 
b) 200 nM 
Area % Report 
 
Data File: C:\EZChrom 
Elite\Enterprise\Projects\Default\Data\Swapnil\Celecoxib\200 nM_PBS_2 
Cel4-2-2013 3-46-34 PMCelecoxib.met 
Method: C:\EZChrom 
Elite\Enterprise\Projects\Default\Method\Swapnil\Celecoxib.met 
Acquired: 4/2/2013 3:47:45 PM 
Printed: 4/2/2013 4:43:25 PM 
Minutes
0 1 2 3 4 5 6 7 8 9 10
m
A
U
-2
0
2
m
A
U
-2
0
2
6
.7
2
0
Multi-Chrom 1 (1: 251 nm, 4 nm)
200 nM_PBS_3 Cel
Retention Time
 
Chromatogram 2. 
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1: 251 nm, 4 
nm Results 
    
Retention 
Time 
Area Area % Height Height % 
6.720 14835 100.00 1697 100.00 
     
Totals     
 14835 100.00 1697 100.00 
 
c) 2000 nM 
Area % Report 
 
Data File: C:\EZChrom 
Elite\Enterprise\Projects\Default\Data\Swapnil\Celecoxib\2000 
nM_PBS_2 Cel4-2-2013 3-57-51 PMCelecoxib.met 
Method: C:\EZChrom 
Elite\Enterprise\Projects\Default\Method\Swapnil\Celecoxib.met 
Acquired: 4/2/2013 3:59:01 PM 
 
Printed: 4/2/2013 4:44:44 PM 
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Minutes
0 1 2 3 4 5 6 7 8 9 10
m
A
U
0
5
10
m
A
U
0
5
10
6
.7
3
3
Multi-Chrom 1 (1: 251 nm, 4 nm)
2000 nM_PBS_3 Cel
Retention Time
 
Chromatogram 3.  
1: 251 nm, 4 
nm Results 
    
Retention 
Time 
Area Area % Height Height % 
6.733 145736 100.00 16811 100.00 
     
Totals     
 145736 100.00 16811 100.00 
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